menu
    • menu
    [{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Chidamide","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Not Applicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Chidamide","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"oral","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Not Applicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Chidamide","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Chidamide","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"Shanghai Public Health Clinical Center","sponsor":"Ascletis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai Public Health Clinical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Hypodermic Injection","sponsorNew":"Shanghai Public Health Clinical Center \/ Ascletis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Public Health Clinical Center \/ Ascletis Pharma"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Chidamide","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chidamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Chidamide

    Menu

    Chidamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chidamide,Rituximab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NMPA Approves Chipscreen's Chidamide with R-CHOP for Diffuse Large B-Cell Lymphoma

                            Details : Chidamide (Epidaza®), an oral subtype-selective HDAC inhibitor, combined with R-CHOP, is approved by NMPA for treating DLBCL with positive MYC and BCL2 expression.

                            Brand Name : Epidaza

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 30, 2024

                            Lead Product(s) : Chidamide,Rituximab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            United BioPharma

                            Taiwan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            United BioPharma

                            Taiwan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-421,Chidamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NIAID/NIH Recognizes the Potency of Ub-421 Against Multi-drug Resistant HIV and Receives the FDA Approval to C...

                            Details : UB-421 is an Fc-aglycosylated, non-T cell depleting and CD4-specific humanized IgG1 derived from the parent murine B4, which binds to discontinuous, conformational epitopes on the HIV-receptor complex, including CD4 (domain 1), and competitively blocks H...

                            Brand Name : UB-421

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 31, 2022

                            Lead Product(s) : UB-421,Chidamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai Public Health Clinical Center

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Shanghai Public Health Clinical Center

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Envafolimab,Chidamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Ascletis Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolim...

                            Details : ASC22 (envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection such as hepatitis B virus (HBV) and HIV.

                            Brand Name : ASC22

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 14, 2022

                            Lead Product(s) : Envafolimab,Chidamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Ascletis Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HUYA Bioscience International

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            HUYA Bioscience International

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chidamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Shenzhen Chipscreen Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HUYABIO International Receives Regulatory Approval for Hiyasta® Monotherapy of Peripheral T-Cell Lymphoma in ...

                            Details : Data from the registration study of HBI-8000 has demonstrated clinically meaningful responses despite the advanced stage of disease and acceptable safety profile to address an important unmet medical need in this patient population.

                            Brand Name : HBI-8000

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2021

                            Lead Product(s) : Chidamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Shenzhen Chipscreen Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            United BioPharma

                            Taiwan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            United BioPharma

                            Taiwan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-421,Chidamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for UB-421 Monotherapy and in Combinati...

                            Details : UB-421 is a strong entry inhibitor of HIV with proven ability to substitute for ART, and it may also enhance CD8 T cell cytotoxicity function and improve immune exhaustions .

                            Brand Name : UB-421

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 18, 2021

                            Lead Product(s) : UB-421,Chidamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HUYA Bioscience International

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            HUYA Bioscience International

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chidamide,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HUYA Bioscience International Presents Positive Data On HBI-8000 at Society for Immunotherapy of Cancer Meetin...

                            Details : Study confirms tolerability and significant anti-tumor activity of HBI-8000 in combination with nivolumab in checkpoint naive melanoma patients.

                            Brand Name : HBI-8000

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2020

                            Lead Product(s) : Chidamide,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HUYA Bioscience International

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            HUYA Bioscience International

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chidamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 Monotherapy Adult T-cell Leukemia...

                            Details : HBI-8000 is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer in China. HBI-8000 targets class I histone deacetylase and suppresses the expression of the viral oncogene HTLV-I bZIP factor, NF-kB and the inf...

                            Brand Name : HBI-8000

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2020

                            Lead Product(s) : Chidamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth